GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Short-Term Debt

Contineum Therapeutics (Contineum Therapeutics) Short-Term Debt : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Short-Term Debt?

Contineum Therapeutics's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

Contineum Therapeutics's annual Short-Term Debt increased from Dec. 2021 ($1.25 Mil) to Dec. 2022 ($3.95 Mil) but then declined from Dec. 2022 ($3.95 Mil) to Dec. 2023 ($0.00 Mil).


Contineum Therapeutics Short-Term Debt Historical Data

The historical data trend for Contineum Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Short-Term Debt Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Short-Term Debt
1.25 3.95 -

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial 3.95 - - - -

Contineum Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Contineum Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics (Contineum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus